Serial entrepreneur and Massachusetts biotech super-star Dr. Robert Langer’s Bind Therapeutics last week launched an initial public offering aimed at raising $70.5 million from shares sold at $15 apiece.
The clinical-stage company, co-founded by Langer and Dr. Omid Farokhzad, is developing nanotech-based solutions for "programmable" therapeutics, starting a pair of cancer drugs.